BR112022026364A2 - Composto macrocíclico, compostos, complexo, uso de um composto, composição farmacêutica, métodos para tratar câncer e para tratar uma condição fibrótica e invenção - Google Patents
Composto macrocíclico, compostos, complexo, uso de um composto, composição farmacêutica, métodos para tratar câncer e para tratar uma condição fibrótica e invençãoInfo
- Publication number
- BR112022026364A2 BR112022026364A2 BR112022026364A BR112022026364A BR112022026364A2 BR 112022026364 A2 BR112022026364 A2 BR 112022026364A2 BR 112022026364 A BR112022026364 A BR 112022026364A BR 112022026364 A BR112022026364 A BR 112022026364A BR 112022026364 A2 BR112022026364 A2 BR 112022026364A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treat
- methods
- macrocyclic
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000003176 fibrotic effect Effects 0.000 title abstract 3
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 238000002144 chemical decomposition reaction Methods 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSTO MACROCÍCLICO, COMPOSTOS, COMPLEXO, USO DE UM COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, MÉTODOS PARA TRATAR CÂNCER E PARA TRATAR UMA CONDIÇÃO FIBRÓTICA E INVENÇÃO. São fornecidos compostos macrocíclicos compreendendo um motivo de ligação de ubiquitina ligase E3 (EULBM) e pelo menos um aminoácido, e métodos de produção e uso de tais EULBMs macrocíclicos para o tratamento de câncer ou de uma afecção fibrótica. Também são fornecidos indutores químicos macrocíclicos heterobifuncionais de degradação (CIDEs) compreendendo um motivo de ligação de ubiquitina ligase E3 (EULBM) e um motivo de ligação da proteína-alvo (TPBM) ligados por pelo menos um aminoácido e métodos para fazer e usar tais CIDEs macrocíclicos heterobifuncionais.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043071P | 2020-06-23 | 2020-06-23 | |
| PCT/US2021/038503 WO2021262731A2 (en) | 2020-06-23 | 2021-06-22 | Macrocyclic compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026364A2 true BR112022026364A2 (pt) | 2023-01-17 |
Family
ID=77207221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026364A BR112022026364A2 (pt) | 2020-06-23 | 2021-06-22 | Composto macrocíclico, compostos, complexo, uso de um composto, composição farmacêutica, métodos para tratar câncer e para tratar uma condição fibrótica e invenção |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220106361A1 (pt) |
| EP (1) | EP4168121A2 (pt) |
| JP (1) | JP2023532233A (pt) |
| KR (1) | KR20230026461A (pt) |
| CN (1) | CN115702026A (pt) |
| AR (1) | AR122707A1 (pt) |
| AU (1) | AU2021297799A1 (pt) |
| BR (1) | BR112022026364A2 (pt) |
| CA (1) | CA3185149A1 (pt) |
| CL (2) | CL2022003643A1 (pt) |
| CO (1) | CO2022018532A2 (pt) |
| CR (1) | CR20220658A (pt) |
| IL (1) | IL299163A (pt) |
| MX (1) | MX2022016454A (pt) |
| PE (1) | PE20230617A1 (pt) |
| TW (1) | TW202219056A (pt) |
| WO (1) | WO2021262731A2 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024020159A1 (en) * | 2022-07-21 | 2024-01-25 | Merck Sharp & Dohme Llc | Macrocyclic peptides targeting kras |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4144233A (en) | 1977-02-16 | 1979-03-13 | The Dow Chemical Company | Method for preparing benzo-(1,3,4)-benzotriazepines |
| US5185331A (en) | 1991-05-14 | 1993-02-09 | Merck & Co., Inc. | Triazolobenzodiazepines |
| CA2340676A1 (en) * | 1998-08-20 | 2000-03-02 | Eli Lilly And Company | Ring modified cyclic peptide analogs |
| TWI447120B (zh) | 2005-05-30 | 2014-08-01 | Mitsubishi Tanabe Pharma Corp | 噻吩并三唑并苯二氮呯化合物、其醫藥上之用途 |
| WO2009084693A1 (ja) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
| EP2496582B1 (en) | 2009-11-05 | 2016-01-27 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
| KR101424989B1 (ko) | 2009-11-05 | 2014-07-31 | 글락소스미스클라인 엘엘씨 | 벤조디아제핀 브로모도메인 억제제 |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| MX362384B (es) | 2010-05-14 | 2019-01-15 | Dana Farber Cancer Inst Inc | Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| WO2011143651A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating metabolism |
| WO2011161031A1 (en) | 2010-06-22 | 2011-12-29 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| US10428026B2 (en) | 2015-09-02 | 2019-10-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
| EP3724216A1 (en) * | 2017-12-15 | 2020-10-21 | Dana Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
-
2021
- 2021-06-22 BR BR112022026364A patent/BR112022026364A2/pt unknown
- 2021-06-22 AR ARP210101716A patent/AR122707A1/es unknown
- 2021-06-22 TW TW110122822A patent/TW202219056A/zh unknown
- 2021-06-22 CR CR20220658A patent/CR20220658A/es unknown
- 2021-06-22 PE PE2022003001A patent/PE20230617A1/es unknown
- 2021-06-22 CN CN202180043710.0A patent/CN115702026A/zh active Pending
- 2021-06-22 CA CA3185149A patent/CA3185149A1/en active Pending
- 2021-06-22 US US17/355,022 patent/US20220106361A1/en active Pending
- 2021-06-22 EP EP21749903.7A patent/EP4168121A2/en active Pending
- 2021-06-22 JP JP2022578964A patent/JP2023532233A/ja active Pending
- 2021-06-22 MX MX2022016454A patent/MX2022016454A/es unknown
- 2021-06-22 KR KR1020237002112A patent/KR20230026461A/ko active Search and Examination
- 2021-06-22 IL IL299163A patent/IL299163A/en unknown
- 2021-06-22 AU AU2021297799A patent/AU2021297799A1/en active Pending
- 2021-06-22 WO PCT/US2021/038503 patent/WO2021262731A2/en active Application Filing
-
2022
- 2022-12-19 CL CL2022003643A patent/CL2022003643A1/es unknown
- 2022-12-21 CO CONC2022/0018532A patent/CO2022018532A2/es unknown
-
2023
- 2023-08-29 CL CL2023002555A patent/CL2023002555A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20230617A1 (es) | 2023-04-14 |
| EP4168121A2 (en) | 2023-04-26 |
| WO2021262731A3 (en) | 2022-02-24 |
| WO2021262731A2 (en) | 2021-12-30 |
| CR20220658A (es) | 2023-04-26 |
| AU2021297799A1 (en) | 2022-12-22 |
| CO2022018532A2 (es) | 2022-12-30 |
| JP2023532233A (ja) | 2023-07-27 |
| TW202219056A (zh) | 2022-05-16 |
| CA3185149A1 (en) | 2021-12-30 |
| CL2022003643A1 (es) | 2023-05-26 |
| CL2023002555A1 (es) | 2024-01-26 |
| MX2022016454A (es) | 2023-03-06 |
| IL299163A (en) | 2023-02-01 |
| AR122707A1 (es) | 2022-09-28 |
| US20220106361A1 (en) | 2022-04-07 |
| CN115702026A (zh) | 2023-02-14 |
| KR20230026461A (ko) | 2023-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020123300A3 (en) | Kras variant mrna molecules | |
| BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
| BR112021017583A2 (pt) | Compostos, composições e métodos para o tratamento de doença | |
| BRPI0513405A (pt) | tienopirimidinas úteis como inibidores de aurora quinase | |
| PH12021550779A1 (en) | Sting agonistic compound | |
| EA202192636A1 (ru) | Композиции и способы, содержащие гидовую рнк ttr и полинуклеотид, кодирующий днк-связывающий агент, гидируемый рнк | |
| EA200700501A1 (ru) | Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества | |
| WO2007048042A3 (en) | Small molecule inhibitors of hiv-1 capsid assembly | |
| BRPI0710331A2 (pt) | Compostos heteroarila monocíclicos para tratamento de câncer e composição | |
| CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
| BR112022026364A2 (pt) | Composto macrocíclico, compostos, complexo, uso de um composto, composição farmacêutica, métodos para tratar câncer e para tratar uma condição fibrótica e invenção | |
| BR112021024010A2 (pt) | Antibióticos macrocíclicos de amplo espectro | |
| WO2019032936A8 (en) | LINCONSAMIDE ANTIBIOTICS AND USES THEREOF | |
| BR112018010267A2 (pt) | antibióticos macrocíclicos de amplo espectro | |
| WO2022235870A8 (en) | Ras inhibitors for the treatment of cancer | |
| BRPI0308606B8 (pt) | compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos | |
| DE602006015837D1 (de) | Formulierungen von tipifarnib zur intravenösen verabreichung | |
| WO2022079290A3 (en) | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof | |
| DK1893213T3 (da) | Kombination af pyrimidylaminobenzamidforbindelser og imatinib til behandling eller forebyggelse af proliferative sygdomme | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| BR112022021918A2 (pt) | Composições e métodos para o tratamento de fibrose cística | |
| BR112022005706A2 (pt) | Inibidores de 1,6-naftiridina substituída de cdk5 | |
| BR112021017710A2 (pt) | Composto, composição farmacêutica, método de tratamento | |
| EP3826629A4 (en) | METHODS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF PANCREATIC CANCER USING 6,8-BIS(BENZYLSULFANYL)OCTANOIC ACID | |
| BRPI0412544A (pt) | métodos de inibição de eclosão de ovo de um ectoparasito, de tratamento ou prevenção de infestação por ectoparasito em hospedeiro e de identificação de composto inibidor da eclosão de ovo de ectoparasito, respectivas composições e usos de agente quelante de metal e de pelo menos um inibidor de metaloprotease |